S&P 500   3,348.77 (-0.35%)
DOW   27,814.27 (+0.08%)
QQQ   267.61 (-1.00%)
AAPL   439.30 (-2.57%)
MSFT   204.61 (-1.75%)
FB   260.19 (-1.07%)
GOOGL   1,486.66 (-0.68%)
AMZN   3,100.00 (-1.53%)
NVDA   435.15 (-2.56%)
CGC   17.28 (-3.63%)
BABA   249.07 (+0.38%)
TSLA   1,374.30 (-3.12%)
GE   6.77 (+1.50%)
MU   48.48 (-1.36%)
AMD   76.72 (-6.71%)
T   30.39 (+0.63%)
F   7.30 (+2.96%)
ACB   10.16 (-0.59%)
GILD   68.11 (-0.58%)
NFLX   470.19 (-2.73%)
DIS   131.63 (+2.21%)
BAC   27.21 (+2.45%)
BA   183.63 (+2.35%)
S&P 500   3,348.77 (-0.35%)
DOW   27,814.27 (+0.08%)
QQQ   267.61 (-1.00%)
AAPL   439.30 (-2.57%)
MSFT   204.61 (-1.75%)
FB   260.19 (-1.07%)
GOOGL   1,486.66 (-0.68%)
AMZN   3,100.00 (-1.53%)
NVDA   435.15 (-2.56%)
CGC   17.28 (-3.63%)
BABA   249.07 (+0.38%)
TSLA   1,374.30 (-3.12%)
GE   6.77 (+1.50%)
MU   48.48 (-1.36%)
AMD   76.72 (-6.71%)
T   30.39 (+0.63%)
F   7.30 (+2.96%)
ACB   10.16 (-0.59%)
GILD   68.11 (-0.58%)
NFLX   470.19 (-2.73%)
DIS   131.63 (+2.21%)
BAC   27.21 (+2.45%)
BA   183.63 (+2.35%)
S&P 500   3,348.77 (-0.35%)
DOW   27,814.27 (+0.08%)
QQQ   267.61 (-1.00%)
AAPL   439.30 (-2.57%)
MSFT   204.61 (-1.75%)
FB   260.19 (-1.07%)
GOOGL   1,486.66 (-0.68%)
AMZN   3,100.00 (-1.53%)
NVDA   435.15 (-2.56%)
CGC   17.28 (-3.63%)
BABA   249.07 (+0.38%)
TSLA   1,374.30 (-3.12%)
GE   6.77 (+1.50%)
MU   48.48 (-1.36%)
AMD   76.72 (-6.71%)
T   30.39 (+0.63%)
F   7.30 (+2.96%)
ACB   10.16 (-0.59%)
GILD   68.11 (-0.58%)
NFLX   470.19 (-2.73%)
DIS   131.63 (+2.21%)
BAC   27.21 (+2.45%)
BA   183.63 (+2.35%)
S&P 500   3,348.77 (-0.35%)
DOW   27,814.27 (+0.08%)
QQQ   267.61 (-1.00%)
AAPL   439.30 (-2.57%)
MSFT   204.61 (-1.75%)
FB   260.19 (-1.07%)
GOOGL   1,486.66 (-0.68%)
AMZN   3,100.00 (-1.53%)
NVDA   435.15 (-2.56%)
CGC   17.28 (-3.63%)
BABA   249.07 (+0.38%)
TSLA   1,374.30 (-3.12%)
GE   6.77 (+1.50%)
MU   48.48 (-1.36%)
AMD   76.72 (-6.71%)
T   30.39 (+0.63%)
F   7.30 (+2.96%)
ACB   10.16 (-0.59%)
GILD   68.11 (-0.58%)
NFLX   470.19 (-2.73%)
DIS   131.63 (+2.21%)
BAC   27.21 (+2.45%)
BA   183.63 (+2.35%)
Log in

OTCMKTS:XCURExicure Stock Price, Forecast & News

$2.33
-0.06 (-2.51 %)
(As of 08/11/2020 03:22 PM ET)
Add
Compare
Today's Range
$2.32
Now: $2.33
$2.47
50-Day Range
$2.24
MA: $2.43
$2.92
52-Week Range
$0.96
Now: $2.33
$3.84
Volume90,494 shs
Average Volume327,674 shs
Market Capitalization$203.06 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Exicure, Inc. engages in the provision of clinical stage biotechnology company. It offers 3-dimensional, spherical nucleic acid architecture unlocks the potential of nucleic acid therapeutics. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in 2011 and is headquartered in Skokie, IL.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.30 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:XCUR
CUSIPN/A
Phone(847) 673-1700

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees27
Market Cap$203.06 million
Next Earnings DateN/A
OptionableNot Optionable
$2.33
-0.06 (-2.51 %)
(As of 08/11/2020 03:22 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive XCUR News and Ratings via Email

Sign-up to receive the latest news and ratings for XCUR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Exicure (OTCMKTS:XCUR) Frequently Asked Questions

How has Exicure's stock price been impacted by COVID-19?

Exicure's stock was trading at $1.66 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, XCUR stock has increased by 40.4% and is now trading at $2.33.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Exicure?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exicure in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Exicure
.

How were Exicure's earnings last quarter?

Exicure Inc (OTCMKTS:XCUR) issued its quarterly earnings data on Thursday, May, 14th. The company reported $0.01 earnings per share for the quarter, topping analysts' consensus estimates of ($0.09) by $0.10. The company had revenue of $9.18 million for the quarter, compared to analyst estimates of $0.40 million.
View Exicure's earnings history
.

What price target have analysts set for XCUR?

4 brokers have issued twelve-month target prices for Exicure's stock. Their forecasts range from $5.00 to $18.00. On average, they expect Exicure's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 329.2% from the stock's current price.
View analysts' price targets for Exicure
.

Has Exicure been receiving favorable news coverage?

News articles about XCUR stock have been trending neutral on Tuesday, InfoTrie reports. The research group ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Exicure earned a daily sentiment score of 0.2 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.
View the latest news about Exicure
.

Who are some of Exicure's key competitors?

What other stocks do shareholders of Exicure own?

Who are Exicure's key executives?

Exicure's management team includes the following people:
  • David A. Giljohann, Chief Executive Officer & Director
  • Matthias Schroff, Chief Operating Officer
  • David S. Snyder, Chief Financial Officer
  • Jocelyn Trokenheim, Vice President & Head-Business Developemnt

What is Exicure's stock symbol?

Exicure trades on the OTCMKTS under the ticker symbol "XCUR."

Who are Exicure's major shareholders?

Exicure's stock is owned by a number of institutional and retail investors. Top institutional investors include Cannell Peter B & Co. Inc. (0.14%), New York State Common Retirement Fund (0.06%), Russell Investments Group Ltd. (0.05%), Private Vista LLC (0.04%), UBS Group AG (0.03%) and State Board of Administration of Florida Retirement System (0.02%). Company insiders that own Exicure stock include Aurasense Llc, Chad A Mirkin, David A Giljohann and David R Walt.
View institutional ownership trends for Exicure
.

Which institutional investors are selling Exicure stock?

XCUR stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd..
View insider buying and selling activity for Exicure
.

Which institutional investors are buying Exicure stock?

XCUR stock was purchased by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Cannell Peter B & Co. Inc., UBS Group AG, State Board of Administration of Florida Retirement System, Private Vista LLC, and Strs Ohio. Company insiders that have bought Exicure stock in the last two years include Chad A Mirkin, David A Giljohann, and David R Walt.
View insider buying and selling activity for Exicure
.

How do I buy shares of Exicure?

Shares of XCUR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Exicure's stock price today?

One share of XCUR stock can currently be purchased for approximately $2.33.

How big of a company is Exicure?

Exicure has a market capitalization of $203.06 million. Exicure employs 27 workers across the globe.

What is Exicure's official website?

The official website for Exicure is www.exicuretx.com.

How can I contact Exicure?

The company can be reached via phone at (847) 673-1700.

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.